Online inquiry

IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11627MR)

This product GTTS-WQ11627MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets LAG3&PDCD1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002286.6; NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3902; 5133
UniProt ID P18627; Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11627MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12443MR IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA NKTR-214
GTTS-WQ12587MR IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA NVS250519
GTTS-WQ15868MR IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA XmAb5871
GTTS-WQ1152MR IVTScrip™ mRNA-Anti-VEGFA, ABP 215(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABP 215
GTTS-WQ6520MR IVTScrip™ mRNA-Anti-ALCAM, CX-191(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CX-191
GTTS-WQ15381MR IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA TRU-016
GTTS-WQ6545MR IVTScrip™ mRNA-Anti-TNF, D2E7(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA D2E7
GTTS-WQ4078MR IVTScrip™ mRNA-Anti-IGF, BI 836(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BI 836
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW